These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 31566013)
1. Drugs under development for the treatment of functional dyspepsia and related disorders. Tack J; Masuy I; Van Den Houte K; Wauters L; Schol J; Vanuytsel T; Vandenberghe A; Carbone F Expert Opin Investig Drugs; 2019 Oct; 28(10):871-889. PubMed ID: 31566013 [No Abstract] [Full Text] [Related]
2. Current and emerging therapeutic options for the management of functional dyspepsia. Vandenberghe A; Schol J; Van den Houte K; Masuy I; Carbone F; Tack J Expert Opin Pharmacother; 2020 Feb; 21(3):365-376. PubMed ID: 31899982 [No Abstract] [Full Text] [Related]
3. Postprandial distress syndrome: stratification and management. Van Den Houte K; Carbone F; Tack J Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):37-46. PubMed ID: 30791841 [TBL] [Abstract][Full Text] [Related]
6. New developments in the treatment of gastroparesis and functional dyspepsia. Tack J; Camilleri M Curr Opin Pharmacol; 2018 Dec; 43():111-117. PubMed ID: 30245474 [TBL] [Abstract][Full Text] [Related]
7. Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia. Porika SK; Veligandla KC; Muni SK; Acharya S; Mehta SC; Sharma AD Adv Ther; 2018 Nov; 35(11):1884-1893. PubMed ID: 30350248 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999 [TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia. Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S Digestion; 2017; 96(1):5-12. PubMed ID: 28605740 [TBL] [Abstract][Full Text] [Related]
10. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. Vanheel H; Carbone F; Valvekens L; Simren M; Tornblom H; Vanuytsel T; Van Oudenhove L; Tack J Am J Gastroenterol; 2017 Jan; 112(1):132-140. PubMed ID: 27958284 [TBL] [Abstract][Full Text] [Related]
11. Fasting and postprandial gastric sensorimotor activity in functional dyspepsia: postprandial distress vs. epigastric pain syndrome. Di Stefano M; Miceli E; Tana P; Mengoli C; Bergonzi M; Pagani E; Corazza GR Am J Gastroenterol; 2014 Oct; 109(10):1631-9. PubMed ID: 25199472 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Xiao YL; Peng S; Tao J; Wang AJ; Lin JK; Hu PJ; Chen MH Am J Gastroenterol; 2010 Dec; 105(12):2626-31. PubMed ID: 20823838 [TBL] [Abstract][Full Text] [Related]
17. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Mayanagi S; Kishino M; Kitagawa Y; Sunamura M Tohoku J Exp Med; 2014 Nov; 234(3):237-40. PubMed ID: 25382232 [TBL] [Abstract][Full Text] [Related]